Get 50% off our best features
SubscribeLogin
Get 50% off our best features
Published

Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated at StockNews.com

Summary by defenseworld.net
Research analysts at StockNews.com initiated coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Get Free Report) in a report issued on Wednesday. The firm set a “hold” rating on the biopharmaceutical company’s stock. Several other brokerages also recently commented on RVNC. Piper Sandler downgraded shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 12th. Guggenheim reiterated…
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources are Center, 50% of the sources lean Right
50% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal